For press inquiries click here to contact us.
The Full Ratchet
Growth Investing in Biotech, Genomics and Pharma (Jim Tananbaum)
The Bio Report
Why Foresite Capital is Betting Big on the Convergence of AI and Biotech
Business Insider
‘We’re a proudly geeky crew:’ A VC that manages $2 billion explains why he plans to stick with investments until they’re profitable
Wall Street Journal
Foresite Capital Closes $668 Million Fund, its Largest Yet
San Francisco Business Times
Fresh $668 million biotech venture fund aims to quench hunger for data
Forbes
Jim Tananbaum Named to Midas List of Top Tech Investors for 4th Year in a Row
Forbes
Foresite Capital CEO Jim Tananbaum Makes His Second Straight Appearance On The Forbes Midas List
Underdog
Jim Tananbaum, CEO & Managing Director, Foresite Capital Interview
WSJ Pro
Foresite Capital’s Vik Bajaj Melds Digital with Life Sciences
Recognitions by unaffiliated third parties should not be construed as a current or past endorsement of Foresite Capital Management, LLC (“Foresite Capital”) or the private funds it manages. The rankings and recognitions published by Forbes are based on information prepared and submitted by Foresite Capital. Third party ratings are not representative of an individual investor’s investment results or the results of Foresite Capital and its funds. Past performance is no guarantee of future results. Please contact Foresite Capital for more detail on the criteria upon which the Forbes Midas List is based.